These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 22187932)

  • 1. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    Pharmacoeconomics; 2012 Feb; 30(2):87-101. PubMed ID: 22187932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
    Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
    Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
    Zindel S; Stock S; Müller D; Stollenwerk B
    BMC Health Serv Res; 2012 Jul; 12():192. PubMed ID: 22776616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
    McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
    J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
    Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Rivaroxaban Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Knee Replacement and Total Hip Replacement: A Systematic Review.
    Rashki Kemmak A; Abutorabi A; Alipour V
    Clin Drug Investig; 2020 Aug; 40(8):715-725. PubMed ID: 32578155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST; Scott LJ; Plosker GL
    Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.
    Holmes M; Carroll C; Papaioannou D
    Pharmacoeconomics; 2012 Feb; 30(2):137-46. PubMed ID: 22185183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.